US EditionOzempic Goes Generic —But Not in the US
2 Articles
2 Articles
Ozempic Goes Generic —But Not in the US
A drug that helped turn Novo Nordisk into Europe's most valuable company is about to lose its monopoly grip across much of the globe. Patent protections on semaglutide—sold as Ozempic for diabetes and Wegovy for weight loss—expire Saturday in several of the world's most populous countries, opening the...
The drug known commercially as Ozempic is about to become generic in several countries of the world, in a change that could profoundly modify access to treatments against diabetes and obesity. Expiration of patents in key markets will enable the production of cheaper versions of semaglutide, the central component of the drug.This process will begin in countries that concentrate about 40% of the world's population, such as India, China, Brazil, C…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
